Insider · CIK 0001866219

Newton Charles W.

Reports to the SEC for 5 companies · LEXINGTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001866219

Forms 4 and 5

Insider transactions

44 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-18	KROSKeros Therapeutics, Inc.S Sale	Director	SSale	−551 sh	$10.30	−$5,675.3	12,114
2026-06-18	NVAXNOVAVAX INC · Stock Option (Right to Buy)A Award	Director	AAward	+21.3K sh	—	—	21,270
2026-06-18	NVAXNOVAVAX INC · Restricted Stock UnitsA Award	Director	AAward	+14.2K sh	—	—	14,180
2026-06-11	KROSKeros Therapeutics, Inc.S Sale	Director	SSale	−550 sh	$10.04	−$5,522	12,665
2026-06-05	CHRSCoherus Oncology, Inc.A Award	Director	AAward	+30K sh	—	—	30,000
2026-06-05	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+60K sh	—	—	60,000
2026-04-25	NVAXNOVAVAX INCM Exercise/Conversion	Director	MExercise/Conversion	+9,520 sh	—	—	9,520
2026-04-25	NVAXNOVAVAX INC · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−9,520 sh	—	—	19,040
2026-03-09	KROSKeros Therapeutics, Inc.A Award	Director	AAward	+13.2K sh	—	—	13,215
2026-03-09	KROSKeros Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.8K sh	—	—	14,788
2025-08-21	LYELLyell Immunopharma, Inc.S Sale	Chief Financial Officer	SSale	−1,453 sh	$10.54	−$15.3K	15,306
2025-08-20	LYELLyell Immunopharma, Inc.A Award	Chief Financial Officer	AAward	+8,000 sh	—	—	16,759
2025-08-12	LYELLyell Immunopharma, Inc.S Sale	Chief Financial Officer	SSale	−136 sh	$10.34	−$1,405.968	8,759
2025-08-11	LYELLyell Immunopharma, Inc.S Sale	Chief Financial Officer	SSale	−131 sh	$10.53	−$1,378.906	8,895
2025-06-12	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+112K sh	—	—	112,000
2025-05-13	2seventy bio, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−17.1K sh	—	—	5,533
2025-05-13	2seventy bio, Inc.U Disposition from Tender	Director	UDisposition from Tender	−5,533 sh	—	—	0
2025-05-13	2seventy bio, Inc.Stock Options (Right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−33.4K sh	—	—	0
2025-05-13	2seventy bio, Inc.Stock Options (Right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−12.1K sh	—	—	0
2025-04-25	NVAXNOVAVAX INC · Stock Option (Right to buy)A Award	Director	AAward	+42.8K sh	—	—	42,840
2025-04-25	NVAXNOVAVAX INC · Restricted Stock UnitsA Award	Director	AAward	+28.6K sh	—	—	28,560
2025-03-17	LYELLyell Immunopharma, Inc.P Purchase	Chief Financial Officer	PPurchase	+200K sh	$0.56	+$112K	200,000
2025-02-10	LYELLyell Immunopharma, Inc.A Award	Chief Financial Officer	AAward	+113K sh	—	—	172,725
2025-02-10	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Chief Financial Officer	AAward	+450K sh	—	—	450,000
2025-02-10	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Chief Financial Officer	AAward	+56.3K sh	—	—	56,250
2024-06-10	2seventy bio, Inc.A Award	Director	AAward	+6,025 sh	—	—	22,625
2024-06-10	2seventy bio, Inc.Stock Options (Right to buy)A Award	Director	AAward	+12.1K sh	—	—	12,050
2024-06-03	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+112K sh	—	—	112,000
2024-03-20	2seventy bio, Inc.A Award	Director	AAward	+16.6K sh	—	—	16,600
2024-03-20	2seventy bio, Inc.Stock Options (Right to buy)A Award	Director	AAward	+33.4K sh	—	—	33,400
2024-02-09	LYELLyell Immunopharma, Inc.A Award	Chief Financial Officer	AAward	+40K sh	—	—	48,729
2024-02-09	LYELLyell Immunopharma, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+400K sh	—	—	400,000
2023-11-16	LYELLyell Immunopharma, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+3.61M sh	—	—	3,612,000
2023-11-16	LYELLyell Immunopharma, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−3.61M sh	—	—	0
2023-11-16	LYELLyell Immunopharma, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+190K sh	—	—	190,000
2023-11-16	LYELLyell Immunopharma, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−190K sh	—	—	0
2023-11-16	LYELLyell Immunopharma, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+516K sh	—	—	516,000
2023-11-16	LYELLyell Immunopharma, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−516K sh	—	—	0
2023-11-16	LYELLyell Immunopharma, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+500K sh	—	—	500,000
2023-11-16	LYELLyell Immunopharma, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−500K sh	—	—	0
2023-06-07	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+38.3K sh	—	—	38,250
2023-02-24	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Chief Financial Officer	AAward	+700K sh	—	—	700,000
2022-05-04	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+54K sh	—	—	54,000
2022-03-16	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Chief Financial Officer	AAward	+500K sh	—	—	500,000

Recent filings

Accepted (ET)
Aug 204
Newton Charles W.0001866219-26-000010
SEC(opens sec.gov)
Jun 234
Newton Charles W.0001104659-26-076922
SEC(opens sec.gov)
Jun 154
Newton Charles W.0001866219-26-000007
SEC(opens sec.gov)
Jun 94
Newton Charles W.0001610717-26-000200
SEC(opens sec.gov)
Apr 284
Newton Charles W.0001104659-26-050457
SEC(opens sec.gov)
Mar 114
Newton Charles W.0001866219-26-000005
SEC(opens sec.gov)
Aug 224
Newton Charles W.0001415889-25-022741
SEC(opens sec.gov)
Aug 134
Newton Charles W.0001415889-25-021691
SEC(opens sec.gov)
Jun 134
Newton Charles W.0001610717-25-000223
SEC(opens sec.gov)
May 154
Newton Charles W.0001562180-25-003881
SEC(opens sec.gov)
Apr 294
Newton Charles W.0001104659-25-040669
SEC(opens sec.gov)

Companies

Address

C/O KEROS THERAPEUTICS, INC. 1050 WALTHAM STREET, SUITE 302

LEXINGTON, MA, 02421